Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Excessive abnormal angiogenesis plays a pivotal role in tumor progression and is a
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …

Glioblastoma is the most common primary central nervous system malignancy and has a
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …

Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in
a proportion of metastatic urothelial cancers,. Biomarkers may facilitate identification of these …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Despite remarkable success in the treatment of hematological malignancies, CAR T-cell
therapies for solid tumors have floundered, in large part due to local immune suppression …

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic
application is limited by toxic inflammatory responses. We assessed the safety and …

Surgical resection is the primary and most effective treatment for most patients with solid
tumors. However, patients suffer from postoperative recurrence and metastasis. In the past …

Targeting membrane proteins could improve the efficacy of T cell–based immunotherapies.
To facilitate the identification of T cell targets, we developed a hybrid genetic screening …

Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated
durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently …